Ajooni Biotech Limited (IN:AJOONI)
:AJOONI
Want to see IN:AJOONI full AI Analyst Report?
AJOONI Stock Chart & Stats
₹5.13
₹0.07(0.90%)
At close: 4:00 PM EST
₹5.13
₹0.07(0.90%)
Day’s Range― - ―
52-Week Range₹3.55 - ₹6.60
Previous CloseN/A
Volume422.93K
Average Volume (3M)354.25K
Market Cap
N/A
Enterprise Value₹833.42M
Total Cash (Recent Filing)₹152.87M
Total Debt (Recent Filing)₹88.71M
Price to Earnings (P/E)11.3
Beta1.00
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding172,243,590
10 Day Avg. Volume263,831
30 Day Avg. Volume354,249
Financial Highlights & Ratios
PEG Ratio-1.89
Price to Book (P/B)1.26
Price to Sales (P/S)0.97
P/FCF Ratio-5.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA 43.2% year-over-year revenue increase signals durable demand expansion in cattle feed and related products. Sustained top-line growth supports capacity utilization, provides room for operating leverage, and underpins longer-term margin improvement as fixed costs are absorbed.
Very Low Leverage / Strong SolvencyExtremely low leverage and a 92.7% equity ratio give the company high solvency and financial flexibility. This capital structure reduces default and refinancing risk, enabling investment in distribution or working capital without near-term debt strain amid commodity cycles.
Improving Profitability MetricsImproving margins (gross 12%, EBITDA 5%, net 2.8%) point to better cost control and pricing execution as volumes rise. Combined with strong revenue growth, this indicates potential sustainable operating leverage and a realistic path to higher earnings conversion over the medium term.
Bears Say
Negative Operating And Free Cash FlowReported negative operating and free cash flow means earnings are not converting to cash, creating reliance on external or financing cash inflows. Over 2-6 months this constrains investment in capacity, working capital buffers, and raises liquidity vulnerability during input cost shocks.
Modest Capital Efficiency / Low ROEA 3.7% ROE indicates limited returns on shareholder capital despite low leverage. Persistently low capital efficiency can restrict reinvestment upside and make it harder to justify new capital allocation, potentially slowing durable shareholder value creation absent margin expansion.
Earnings Not Converting To CashAn unfavorable OCF-to-net-income ratio shows reported profits are not reliably turning into cash, exposing the business to working-capital swings and raw-material cost volatility. This structural conversion gap elevates medium-term liquidity and funding risk.
Ajooni Biotech Limited News
AJOONI FAQ
What was Ajooni Biotech Limited’s price range in the past 12 months?
Ajooni Biotech Limited lowest stock price was ₹3.55 and its highest was ₹6.60 in the past 12 months.
What is Ajooni Biotech Limited’s market cap?
Currently, no data Available
When is Ajooni Biotech Limited’s upcoming earnings report date?
Ajooni Biotech Limited’s upcoming earnings report date is May 11, 2026 which is in 9 days.
How were Ajooni Biotech Limited’s earnings last quarter?
Ajooni Biotech Limited released its earnings results on Jan 30, 2026. The company reported ₹0.096 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.096.
Is Ajooni Biotech Limited overvalued?
According to Wall Street analysts Ajooni Biotech Limited’s price is currently Overvalued.
Does Ajooni Biotech Limited pay dividends?
Ajooni Biotech Limited does not currently pay dividends.
What is Ajooni Biotech Limited’s EPS estimate?
Ajooni Biotech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ajooni Biotech Limited have?
Ajooni Biotech Limited has 172,243,590 shares outstanding.
What happened to Ajooni Biotech Limited’s price movement after its last earnings report?
Ajooni Biotech Limited reported an EPS of ₹0.096 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.302%.
Which hedge fund is a major shareholder of Ajooni Biotech Limited?
Currently, no hedge funds are holding shares in IN:AJOONI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ajooni Biotech Limited
Ajooni Biotech Limited manufactures and sells animal feed in India. The company offers cattle feeds and feed supplements. Ajooni Biotech Limited was incorporated in 2010 and is based in Mohali, India.
Technical Analysis
Balaxi Pharmaceuticals Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
―
Lasa Supergenerics Ltd.
―
Vaishali Pharma Ltd.
―